COST

1,026.56

+2.01%↑

PG

163.14

+0.44%↑

KO

72.16

+0.75%↑

PM

170.41

+0.53%↑

PEP

132.08

+0.77%↑

COST

1,026.56

+2.01%↑

PG

163.14

+0.44%↑

KO

72.16

+0.75%↑

PM

170.41

+0.53%↑

PEP

132.08

+0.77%↑

COST

1,026.56

+2.01%↑

PG

163.14

+0.44%↑

KO

72.16

+0.75%↑

PM

170.41

+0.53%↑

PEP

132.08

+0.77%↑

COST

1,026.56

+2.01%↑

PG

163.14

+0.44%↑

KO

72.16

+0.75%↑

PM

170.41

+0.53%↑

PEP

132.08

+0.77%↑

COST

1,026.56

+2.01%↑

PG

163.14

+0.44%↑

KO

72.16

+0.75%↑

PM

170.41

+0.53%↑

PEP

132.08

+0.77%↑

Search

Lifecore Biomedical Inc

Atvērts

SektorsPatēriņa aizsardzības

6.86 2.08

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

6.53

Max

6.88

Galvenie mērījumi

By Trading Economics

Ienākumi

-8.2M

-15M

Pārdošana

2.6M

35M

P/E

Sektora vidējais

201.137

42.52

EPS

-0.253

Peļņas marža

-42.012

Darbinieki

524

EBITDA

-5.5M

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

62M

236M

Iepriekšējā atvēršanas cena

4.78

Iepriekšējā slēgšanas cena

6.86

Ziņu noskaņojums

By Acuity

13%

87%

7 / 151 Rangs Consumer defensive

Lifecore Biomedical Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 15. maijs 22:52 UTC

Peļņas
Galvenie tirgus virzītāji

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

2025. g. 15. maijs 20:37 UTC

Top Ziņas
Peļņas

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

2025. g. 16. maijs 00:00 UTC

Tirgus saruna

Xero Bull Stays Positive on Cost Outlook -- Market Talk

2025. g. 15. maijs 23:47 UTC

Tirgus saruna

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

2025. g. 15. maijs 23:38 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 15. maijs 23:38 UTC

Tirgus saruna

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

2025. g. 15. maijs 23:14 UTC

Top Ziņas

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

2025. g. 15. maijs 22:46 UTC

Top Ziņas
Iegādes, apvienošanās, pārņemšana

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

2025. g. 15. maijs 22:46 UTC

Iegādes, apvienošanās, pārņemšana

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

2025. g. 15. maijs 22:46 UTC

Iegādes, apvienošanās, pārņemšana

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

2025. g. 15. maijs 22:46 UTC

Iegādes, apvienošanās, pārņemšana

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

2025. g. 15. maijs 21:58 UTC

Peļņas

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

2025. g. 15. maijs 21:24 UTC

Peļņas

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

2025. g. 15. maijs 20:56 UTC

Tirgus saruna

U.S. Spending Downturn Could Lie Ahead -- Market Talk

2025. g. 15. maijs 20:54 UTC

Tirgus saruna
Peļņas

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

2025. g. 15. maijs 20:54 UTC

Peļņas

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

2025. g. 15. maijs 20:51 UTC

Peļņas

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

2025. g. 15. maijs 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 15. maijs 20:50 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

2025. g. 15. maijs 20:50 UTC

Peļņas

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

2025. g. 15. maijs 20:47 UTC

Peļņas

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

2025. g. 15. maijs 20:47 UTC

Peļņas

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

2025. g. 15. maijs 20:47 UTC

Peļņas

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

2025. g. 15. maijs 20:47 UTC

Peļņas

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

2025. g. 15. maijs 20:37 UTC

Peļņas

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

2025. g. 15. maijs 20:37 UTC

Peļņas

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

2025. g. 15. maijs 20:37 UTC

Peļņas

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

2025. g. 15. maijs 20:37 UTC

Peļņas

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

2025. g. 15. maijs 20:26 UTC

Top Ziņas

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

2025. g. 15. maijs 20:25 UTC

Peļņas

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Lifecore Biomedical Inc Prognoze

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

1

Pirkt

1

Turēt

0

Pārdot

Noskaņojums

By Acuity

7 / 151 Rangs Patēriņa aizsardzības

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Lifecore Biomedical Inc

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.